Browse Category

CEO Changes News 3 October 2025 - 25 December 2025

The Coca-Cola Company (KO) News, Forecasts and Analysis on Dec. 25, 2025: CEO Transition, Costa Coffee Talks, and 2026 Outlook

The Coca-Cola Company (KO) News, Forecasts and Analysis on Dec. 25, 2025: CEO Transition, Costa Coffee Talks, and 2026 Outlook

Published: December 25, 2025 As 2025 closes, The Coca-Cola Company (NYSE: KO) is entering 2026 with three storylines shaping investor expectations: a major leadership transition, fresh signals that Coca-Cola is still willing to reshape its portfolio and bottling footprint, and
Woodside Energy Group Ltd Stock (ASX:WDS, NYSE:WDS) Drops as CEO Meg O’Neill Exits for BP: Latest News, Analyst Forecasts, and What to Watch Next

Woodside Energy Group Ltd Stock (ASX:WDS, NYSE:WDS) Drops as CEO Meg O’Neill Exits for BP: Latest News, Analyst Forecasts, and What to Watch Next

Woodside Energy Group Ltd stock pulled back on Thursday, 18 December 2025, after the company confirmed a sudden leadership change: CEO and Managing Director Meg O’Neill has resigned to take the top job at BP, triggering an immediate CEO succession
Coca-Cola Stock (KO) Outlook: CEO Transition, Costa Coffee Sale Talks, Dividend, and What to Watch Next Week (Updated Dec. 14, 2025)

Coca-Cola Stock (KO) Outlook: CEO Transition, Costa Coffee Sale Talks, Dividend, and What to Watch Next Week (Updated Dec. 14, 2025)

Updated Sunday, Dec. 14, 2025 (markets closed). Coca-Cola (NYSE: KO) ended last week at $70.52, up about 0.7% week-over-week, as investors digested two headline catalysts: a planned CEO handoff in 2026 and last-ditch negotiations to salvage a Costa Coffee sale.
14 December 2025
Lululemon CEO Calvin McDonald to Step Down: What It Means for LULU Stock Price, Earnings Outlook, and Wall Street Forecasts (Dec. 12, 2025)

Lululemon CEO Calvin McDonald to Step Down: What It Means for LULU Stock Price, Earnings Outlook, and Wall Street Forecasts (Dec. 12, 2025)

Lululemon Athletica (NASDAQ: LULU) is heading into 2026 with a major leadership transition—and investors are trying to decide whether this is the reset the brand needs, or another sign that its North American growth engine is still sputtering. Late Thursday,
RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)

RXRX Stock Today: Insider Selling, CEO Transition and Trial Catalyst Shape Recursion Pharmaceuticals’ Outlook (December 2025)

Recursion Pharmaceuticals (NASDAQ: RXRX), one of the highest‑profile AI‑driven drug discovery names, is back under the microscope. As of the December 5, 2025 close, RXRX stock traded around $4.71, giving the company a market capitalization of roughly $2.5 billion and
Go toTop